Capital Fund Management (CFM)
CORT icon

Capital Fund Management (CFM)’s Corcept Therapeutics CORT Stock Holding History

Capital Fund Management (CFM)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Buy
184,231
+57,802
+46% +$3.49M 0.07% 398
2026
Q1 		$5.1M Buy
126,429
+28,769
+29% +$1.08M 0.02% 884
2025
Q4 		$3.4M Sell
97,660
-62,784
-39% -$4.93M 0.01% 1410
2025
Q3 		$13.3M Buy
160,444
+76,015
+90% +$5.5M 0.03% 688
2025
Q2 		$6.2M Sell
84,429
-23,710
-22% -$1.72M 0.02% 1008
2025
Q1 		$12.4M Sell
108,139
-12,867
-11% -$783K 0.04% 606
2024
Q4 		$6.1M Sell
121,006
-28,991
-19% -$1.52M 0.02% 984
2024
Q3 		$6.94M Buy
149,997
+56,100
+60% +$1.99M 0.02% 870
2024
Q2 		$3.05M Sell
93,897
-39,282
-29% -$1.08M 0.01% 1200
2024
Q1 		$3.35M Buy
133,179
+55,342
+71% +$1.31M 0.01% 1216
2023
Q4 		$2.53M Buy
77,837
+12,637
+19% +$347K 0.01% 1413
2023
Q3 		$1.78M Buy
65,200
+52,020
+395% +$1.51M 0.01% 1415
2023
Q2 		$293K Sell
13,180
-7
-0.1% -$161 ﹤0.01% 1627
2023
Q1 		$286K Sell
13,187
-5,538
-30% -$121K ﹤0.01% 1508
2022
Q4 		$380K Buy
+18,725
New +$469K ﹤0.01% 1309
2022
Q3 		– Sell
-18,594
Closed -$442K – 1439
2022
Q2 		$442K Buy
+18,594
New +$405K ﹤0.01% 1270
2021
Q1 		– Sell
-25,965
Closed -$679K – 1327
2020
Q4 		$679K Buy
25,965
+9,705
+60% +$204K 0.01% 1077
2020
Q3 		$283K Buy
+16,260
New +$259K ﹤0.01% 1134
2020
Q2 		– Sell
-10,172
Closed -$121K – 1115
2020
Q1 		$121K Buy
+10,172
New +$126K ﹤0.01% 1468
2018
Q4 		– Sell
-540,818
Closed -$7.58M – 1902
2018
Q3 		$7.58M Buy
540,818
+229,969
+74% +$3.21M 0.04% 595
2018
Q2 		$4.89M Buy
310,849
+143,801
+86% +$2.5M 0.03% 746
2018
Q1 		$2.75M Buy
+167,048
New +$3.1M 0.02% 893

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Fund Management (CFM)'s CORT Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its Corcept Therapeutics (CORT) stake by 46% in Q2 2026, buying an estimated $3.49M and bringing the position to 184,231 shares worth $16M. The position accounts for 0.07% of the portfolio, ranked #398.

Capital Fund Management (CFM) first reported a position in CORT in Q1 2018 and has held it in 22 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Capital Fund Management (CFM) held 184,231 shares of Corcept Therapeutics worth $16M as of Q2 2026.
  • Capital Fund Management (CFM) bought 57,802 Corcept Therapeutics shares in Q2 2026, an estimated $3.49M.
  • Corcept Therapeutics made up 0.07% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #398 holding.
  • Capital Fund Management (CFM) first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 22 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.